Trade

with

Insmed Inc
(NASDAQ: INSM)
AdChoices
14.27
-0.06
-0.42%
After Hours :
14.27
0.00
0.00%

Open

14.50

Previous Close

14.33

Volume (Avg)

465.86k (785.84k)

Day's Range

13.92-14.52

52Wk Range

11.25-22.29

Market Cap.

560.57M

Dividend Rate ( Yield )

-

Beta

0.50

Shares Outstanding

39.28M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 11.50M

    • Net Income

    • -56.07M

    • Market Cap.

    • 560.57M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.50

    • Forward P/E

    • -8.94

    • Price/Sales

    • -

    • Price/Book Value

    • 5.03

    • Price/Cash flow

    • -8.67

      • EBITDA

      • -54.20M

      • Return on Capital %

      • -49.21

      • Return on Equity %

      • -65.58

      • Return on Assets %

      • -49.21

      • Book Value/Share

      • 2.84

      • Shares Outstanding

      • 39.28M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 30.50

        • Credit Rating

        • -

        • Analysts

        • 2

        • EPS Estimate

        • -1.60

        • Cashflow Estimate

        • -1.16

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -0.34

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -

            • 82.75

            • Pre-Tax Margin

            • -

            • 39.38

            • Net Profit Margin

            • -

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.15

              • 0.76

              • Current Ratio

              • 3.97

              • 2.92

              • Quick Ratio

              • 3.79

              • 2.35

              • Interest Coverage

              • -31.30

              • 38.02

              • Leverage Ratio

              • 1.35

              • 2.21

              • Book Value/Share

              • 2.84

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -7.44

                • 217.39

                • P/E Ratio 5-Year High

                • -12.16

                • 634.30

                • P/E Ratio 5-Year Low

                • -1.44

                • 124.82

                • Price/Sales Ratio

                • -

                • 9.52

                • Price/Book Value

                • 4.80

                • 8.61

                • Price/Cash Flow Ratio

                • -8.67

                • 50.51

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -65.58

                    (14.90)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -49.21

                    (14.60)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -53.60

                    (16.50)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • -

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -55.02M
                  Operating Margin
                  -478.39
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -8.67
                  Ownership

                  Institutional Ownership

                  87.04%

                  Top 10 Institutions

                  49.69%

                  Mutual Fund Ownership

                  48.94%

                  Float

                  83.50%

                  5% / Insider Ownership

                  11.56%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity VIP Growth Portfolio

                  •  

                    1,332,202

                  • 14.39

                  • 3.39

                  • Fidelity® Select Health Care Portfolio

                  •  

                    1,300,220

                  • 51.02

                  • 3.31

                  • Pictet-Biotech

                  •  

                    1,168,468

                  • 0.07

                  • 2.92

                  • SPDR® S&P Biotech ETF

                  •  

                    1,153,007

                  • -1.92

                  • 3.22

                  • Franklin Biotechnology Discovery

                  •  

                    932,700

                  • 50.73

                  • 2.37

                  • Fidelity® Advisor Small Cap Opps Fund

                  •  

                    875,535

                  • 4.64

                  • 2.23

                  • Fidelity Advisor® Equity Growth Fund

                  •  

                    744,220

                  • 16.03

                  • 1.89

                  • iShares Russell 2000 (AU)

                  •  

                    739,886

                  • -1.46

                  • 2.07

                  • Vanguard Total Stock Mkt Idx

                  •  

                    653,994

                  • 0.00

                  • 1.66

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity Management and Research Company

                  •  

                    5,866,475

                  • +0.02%

                  • 14.94

                  • Sectoral Asset Management Inc

                  •  

                    1,985,738

                  • +69.41%

                  • 5.06

                  • Perceptive Advisors LLC

                  •  

                    1,800,000

                  • +429.41%

                  • 4.58

                  • State Street Corp

                  •  

                    1,689,523

                  • +15.56%

                  • 4.30

                  • Millennium Management LLC

                  •  

                    1,520,896

                  • -7.53%

                  • 3.87

                  • Deerfield Management Co

                  •  

                    1,205,234

                  • -40.22%

                  • 3.07

                  • J.P. Morgan Investment Management Inc.

                  •  

                    1,173,512

                  • +44.66%

                  • 2.99

                  • BlackRock Fund Advisors

                  •  

                    1,153,343

                  • -17.69%

                  • 2.94

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Growth

                  Insmed, Inc. was incorporated in the Commonwealth of Virginia on November 29, 1999. The Company is a biopharmaceutical company engaged in developing and commercializing inhaled therapies for patients battling serious lung diseases th...moreat are often life threatening. Its lead product candidate, ARIKAYCE, or liposomal amikacin for inhalation, is a once-a-day inhaled antibiotic treatment engineered to deliver an anti-infective directly to the site of serious lung infections. It is currently conducting a phase 2 clinical trial in the United States and Canada of ARIKAYCE in patients who have lung infections caused by non-tuberculous mycobacteria. In 2013, it concluded a phase 3 clinical trial in Europe and Canada of ARIKAYCE in cystic fibrosis patients who have lung infections caused by Pseudomonas aerugino...moresa. The Company intends to develop ARIKAYCE to broaden the non-tuberculous mycobacteria indication and for additional indications beyond Pseudomonas in cystic fibrosis and non-tuberculous mycobacteria. ARIKAYCE received orphan drug status in the US and Europe for the treatment of non-tuberculous mycobacteria. The Company’s registered trademarks are Insmed, ARIKACE, ARIKAYCE, and IPLEX. Its second proprietary compound is IPLEX, which is IGF-1, with its natural binding protein, IGFBP-3. IPLEX is no longer a development priority for the Company. Its competitors include pharmaceutical and biotechnology companies that have approved therapies or therapies in development for the treatment of chronic lung infections.lessless

                  Key People

                  Mr. William H. Lewis

                  CEO/Director/President

                  Donald J. Hayden,Jr

                  Chairman of the Board/Director

                  Andrew Drechsler

                  CFO/Chief Accounting Officer

                  Bruce Voss

                  Managing Director

                  Wes Kaupinen

                  Vice President, Divisional

                  • Insmed Inc

                  • 9 Deer Park Drive

                  • Monmouth Junction, NJ 08852

                  • USA.Map

                  • Phone: +1 732 997-4600

                  • Fax: -

                  • insmed.com

                  Incorporated

                  1999

                  Employees

                  61

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: